Effect of BN 50739, a new platelet activating factor antagonist, on ischaemia induced ventricular arrhythmias in isolated working rat hearts

Matyas Koltai, A. Tósaki, David Hosford, André Esanu, Pierre Braquet

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Study objective - The aim was to investigate the role of platelet activating factor (PAF) in myocardial ischaemia by using BN 50739, a new specific PAF receptor antagonist with a hetrazepine framework.Design - Isolated working rat hearts were subjected to regional ischaemia, induced by ligation of the left main coronary artery for 30 min, followed by reperfusion. BN 50739 was applied at concentrations of 10-7, 10-6, 10-5 and 5 × 10-5 M, and its effects on the incidence of ischaemia induced and reperfusion induced ventricular tachycardia and ventricular fibrillation and heart functions, such as heart rate, coronary flow, aortic flow, left ventricular developed pressure (LVDP), its first derivative (LvdP/dtmax), and left ventricular end diastolic pressure (LVEDP), were determined.Experimental material - Studies were performed on isolated working hearts of male Sprague-Dawley rats weighing 300-360 g. Hearts were perfused with BN 50739 dissolved in dimethylsulphoxide. Control hearts were perfused with the vehicle.Measurements and main results - Regional ischaemia triggered ventricular arrhythmias showing high incidence between 12 and 20 min with peak appearance at 16 min. BN 50739 induced dose dependent protection against ventricular tachycardia and fibrillation: incidences declined from their respective control values of 91% and 75% to 33% (p<0.05) and 8% (p<0.05) after exposure to 10-5 M, and to 25% (p<0.05) and 8% (p<0.05) after exposure to 5 × 10-5 M concentrations. Reperfusion of the ischaemic myocardium resulted in an immediate appearance of ventricular tachycardia and fibrillation, but these were not suppressed by the PAF antagonist. Regional ischaemia slightly reduced heart rate, markedly decreased coronary flow, aortic flow, LVDP and LvdP/dtmax, and increased LVEDP. With the exception of LVEDP, these variables were not influenced by the drug. BN 50739, applied at a concentration of 5 × 10-5 M, reduced LVEDP significantly during the whole ischaemic period.Conclusions - Under in vitro conditions PAF is likely to be involved in the genesis of ischaemia induced ventricular arrhythmias since BN 50739, a specific PAF receptor antagonist, exerts a protective effect against these rhythm disturbances. This suggests that PAF antagonists may have benefit in the clinical management of acute myocardial ischaemia.

Original languageEnglish
Pages (from-to)391-397
Number of pages7
JournalCardiovascular Research
Volume25
Issue number5
DOIs
Publication statusPublished - Jan 1 1991

Fingerprint

Platelet Activating Factor
Cardiac Arrhythmias
Ischemia
Ventricular Fibrillation
Ventricular Tachycardia
Blood Pressure
Reperfusion
Ventricular Pressure
Myocardial Ischemia
Incidence
Heart Rate
Dimethyl Sulfoxide
Ligation
Sprague Dawley Rats
BN 50739
Coronary Vessels
Myocardium
Pharmaceutical Preparations

Keywords

  • Arrhythmias
  • Heart
  • Hetrazepine
  • In vitro
  • Ischaemia
  • Myocardial function
  • Platelet activating factor PAF antagonist
  • Reperfusion

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Effect of BN 50739, a new platelet activating factor antagonist, on ischaemia induced ventricular arrhythmias in isolated working rat hearts. / Koltai, Matyas; Tósaki, A.; Hosford, David; Esanu, André; Braquet, Pierre.

In: Cardiovascular Research, Vol. 25, No. 5, 01.01.1991, p. 391-397.

Research output: Contribution to journalReview article

@article{68ced6154f664a968cd46bd43ef63925,
title = "Effect of BN 50739, a new platelet activating factor antagonist, on ischaemia induced ventricular arrhythmias in isolated working rat hearts",
abstract = "Study objective - The aim was to investigate the role of platelet activating factor (PAF) in myocardial ischaemia by using BN 50739, a new specific PAF receptor antagonist with a hetrazepine framework.Design - Isolated working rat hearts were subjected to regional ischaemia, induced by ligation of the left main coronary artery for 30 min, followed by reperfusion. BN 50739 was applied at concentrations of 10-7, 10-6, 10-5 and 5 × 10-5 M, and its effects on the incidence of ischaemia induced and reperfusion induced ventricular tachycardia and ventricular fibrillation and heart functions, such as heart rate, coronary flow, aortic flow, left ventricular developed pressure (LVDP), its first derivative (LvdP/dtmax), and left ventricular end diastolic pressure (LVEDP), were determined.Experimental material - Studies were performed on isolated working hearts of male Sprague-Dawley rats weighing 300-360 g. Hearts were perfused with BN 50739 dissolved in dimethylsulphoxide. Control hearts were perfused with the vehicle.Measurements and main results - Regional ischaemia triggered ventricular arrhythmias showing high incidence between 12 and 20 min with peak appearance at 16 min. BN 50739 induced dose dependent protection against ventricular tachycardia and fibrillation: incidences declined from their respective control values of 91{\%} and 75{\%} to 33{\%} (p<0.05) and 8{\%} (p<0.05) after exposure to 10-5 M, and to 25{\%} (p<0.05) and 8{\%} (p<0.05) after exposure to 5 × 10-5 M concentrations. Reperfusion of the ischaemic myocardium resulted in an immediate appearance of ventricular tachycardia and fibrillation, but these were not suppressed by the PAF antagonist. Regional ischaemia slightly reduced heart rate, markedly decreased coronary flow, aortic flow, LVDP and LvdP/dtmax, and increased LVEDP. With the exception of LVEDP, these variables were not influenced by the drug. BN 50739, applied at a concentration of 5 × 10-5 M, reduced LVEDP significantly during the whole ischaemic period.Conclusions - Under in vitro conditions PAF is likely to be involved in the genesis of ischaemia induced ventricular arrhythmias since BN 50739, a specific PAF receptor antagonist, exerts a protective effect against these rhythm disturbances. This suggests that PAF antagonists may have benefit in the clinical management of acute myocardial ischaemia.",
keywords = "Arrhythmias, Heart, Hetrazepine, In vitro, Ischaemia, Myocardial function, Platelet activating factor PAF antagonist, Reperfusion",
author = "Matyas Koltai and A. T{\'o}saki and David Hosford and Andr{\'e} Esanu and Pierre Braquet",
year = "1991",
month = "1",
day = "1",
doi = "10.1093/cvr/25.5.391",
language = "English",
volume = "25",
pages = "391--397",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Effect of BN 50739, a new platelet activating factor antagonist, on ischaemia induced ventricular arrhythmias in isolated working rat hearts

AU - Koltai, Matyas

AU - Tósaki, A.

AU - Hosford, David

AU - Esanu, André

AU - Braquet, Pierre

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Study objective - The aim was to investigate the role of platelet activating factor (PAF) in myocardial ischaemia by using BN 50739, a new specific PAF receptor antagonist with a hetrazepine framework.Design - Isolated working rat hearts were subjected to regional ischaemia, induced by ligation of the left main coronary artery for 30 min, followed by reperfusion. BN 50739 was applied at concentrations of 10-7, 10-6, 10-5 and 5 × 10-5 M, and its effects on the incidence of ischaemia induced and reperfusion induced ventricular tachycardia and ventricular fibrillation and heart functions, such as heart rate, coronary flow, aortic flow, left ventricular developed pressure (LVDP), its first derivative (LvdP/dtmax), and left ventricular end diastolic pressure (LVEDP), were determined.Experimental material - Studies were performed on isolated working hearts of male Sprague-Dawley rats weighing 300-360 g. Hearts were perfused with BN 50739 dissolved in dimethylsulphoxide. Control hearts were perfused with the vehicle.Measurements and main results - Regional ischaemia triggered ventricular arrhythmias showing high incidence between 12 and 20 min with peak appearance at 16 min. BN 50739 induced dose dependent protection against ventricular tachycardia and fibrillation: incidences declined from their respective control values of 91% and 75% to 33% (p<0.05) and 8% (p<0.05) after exposure to 10-5 M, and to 25% (p<0.05) and 8% (p<0.05) after exposure to 5 × 10-5 M concentrations. Reperfusion of the ischaemic myocardium resulted in an immediate appearance of ventricular tachycardia and fibrillation, but these were not suppressed by the PAF antagonist. Regional ischaemia slightly reduced heart rate, markedly decreased coronary flow, aortic flow, LVDP and LvdP/dtmax, and increased LVEDP. With the exception of LVEDP, these variables were not influenced by the drug. BN 50739, applied at a concentration of 5 × 10-5 M, reduced LVEDP significantly during the whole ischaemic period.Conclusions - Under in vitro conditions PAF is likely to be involved in the genesis of ischaemia induced ventricular arrhythmias since BN 50739, a specific PAF receptor antagonist, exerts a protective effect against these rhythm disturbances. This suggests that PAF antagonists may have benefit in the clinical management of acute myocardial ischaemia.

AB - Study objective - The aim was to investigate the role of platelet activating factor (PAF) in myocardial ischaemia by using BN 50739, a new specific PAF receptor antagonist with a hetrazepine framework.Design - Isolated working rat hearts were subjected to regional ischaemia, induced by ligation of the left main coronary artery for 30 min, followed by reperfusion. BN 50739 was applied at concentrations of 10-7, 10-6, 10-5 and 5 × 10-5 M, and its effects on the incidence of ischaemia induced and reperfusion induced ventricular tachycardia and ventricular fibrillation and heart functions, such as heart rate, coronary flow, aortic flow, left ventricular developed pressure (LVDP), its first derivative (LvdP/dtmax), and left ventricular end diastolic pressure (LVEDP), were determined.Experimental material - Studies were performed on isolated working hearts of male Sprague-Dawley rats weighing 300-360 g. Hearts were perfused with BN 50739 dissolved in dimethylsulphoxide. Control hearts were perfused with the vehicle.Measurements and main results - Regional ischaemia triggered ventricular arrhythmias showing high incidence between 12 and 20 min with peak appearance at 16 min. BN 50739 induced dose dependent protection against ventricular tachycardia and fibrillation: incidences declined from their respective control values of 91% and 75% to 33% (p<0.05) and 8% (p<0.05) after exposure to 10-5 M, and to 25% (p<0.05) and 8% (p<0.05) after exposure to 5 × 10-5 M concentrations. Reperfusion of the ischaemic myocardium resulted in an immediate appearance of ventricular tachycardia and fibrillation, but these were not suppressed by the PAF antagonist. Regional ischaemia slightly reduced heart rate, markedly decreased coronary flow, aortic flow, LVDP and LvdP/dtmax, and increased LVEDP. With the exception of LVEDP, these variables were not influenced by the drug. BN 50739, applied at a concentration of 5 × 10-5 M, reduced LVEDP significantly during the whole ischaemic period.Conclusions - Under in vitro conditions PAF is likely to be involved in the genesis of ischaemia induced ventricular arrhythmias since BN 50739, a specific PAF receptor antagonist, exerts a protective effect against these rhythm disturbances. This suggests that PAF antagonists may have benefit in the clinical management of acute myocardial ischaemia.

KW - Arrhythmias

KW - Heart

KW - Hetrazepine

KW - In vitro

KW - Ischaemia

KW - Myocardial function

KW - Platelet activating factor PAF antagonist

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=85047676393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047676393&partnerID=8YFLogxK

U2 - 10.1093/cvr/25.5.391

DO - 10.1093/cvr/25.5.391

M3 - Review article

VL - 25

SP - 391

EP - 397

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 5

ER -